PARP抑制剂HD199胶囊的研制

doi:10.16085/j.issn.1000-6613.2019-1484

化工进展 ›› 2020, Vol. 39 ›› Issue (6): 2447-2452.DOI: 10.16085/j.issn.1000-6613.2019-1484

PARP抑制剂HD199胶囊的研制

徐克耐¹^,²(), 王国成², 王征¹(), 李德馨², 李宏玲²

^1.天津大学药物科学与技术学院，天津 300072
^2.天士力控股集团有限公司天士力研究院，天津 300400

出版日期:2020-06-05 发布日期:2020-06-16
通讯作者: 王征
作者简介:徐克耐（1988—），女，硕士研究生，研究方向为药物制剂与药物分析。E-mail：758478158@qq.com。
基金资助:
重大新药创制(2012ZX09103-101-031)

Optimization of fabrication technology of the PARP inhibitor HD199

Kenai XU¹^,²(), Guocheng WANG², Zheng WANG¹(), Dexin LI², Hongling LI²

^1.School of Pharmaceutical Science and Technology, Tianjin University, Tianjin 300072, China
^2.Tasly Academy, Tasly Holding Group Co. , Ltd. , Tianjin 300410, China

Online:2020-06-05 Published:2020-06-16
Contact: Zheng WANG

摘要/Abstract

摘要：

为了克服新型二磷酸腺苷核糖多聚酶PARP抑制剂HD199原料药流动性不佳、黏度大的问题，本文开发出工艺简单易行、方便调整剂量、质量可控的临床研究使用HD199胶囊剂。通过研究助流剂微粉硅胶和稀释剂种类及用量对HD199粉体性质和溶出度的影响，考察原辅料相容性及工艺重现性，筛选确定HD199胶囊的处方组成。HD199流动性和填充性明显改善，HD199休止角由55.5°降低到45.6°，压缩度由44.4%下降到30.7%；原辅料相容性好，各实验条件下，所研究的各种辅料对HD199的稳定性几乎没有影响，有关物质的改变与API相似；优选的处方组成为HD199/微粉硅胶/乳糖/硬脂酸镁（质量比为1∶0.075∶1.5∶0.025）。研制的HD199胶囊溶出行为理想，工艺重现性佳，适于放大生产。

关键词: PARP抑制剂, HD199胶囊, 流动性, 溶出度, 原辅料相容性

Abstract:

This paper aimed to solve the problem of poor fluidity of HD199, a new PARP (poly ADP-ribose polymerase) inhibitor, and to prepare quality-controllable HD199 capsules with simple and feasible process for phase I clinical studies. The formulation of HD199 capsules was studied by investigating the effects of excipient type and quantity on the powder characters and dissolution profiles. The rest angle of HD199 decreased from 55.5° to 45.6° and the compressibility decreased from 44.4% to 30.7%. Compatibility of raw materials and process reproducibility were also studied. Under various test conditions, the studied excipients had little effect on the stability of HD199, and the change of related substances was similar to that of API. The optimized formulation with good compatibility was as follows: HD199/colloidal silicon dioxide/lactose/magnesium stearate (mass fraction was 1∶0.075∶1.5∶0.025). HD199 capsules, which had high dissolution rate with good reproducibility, were successfully prepared and suitable for scale-up production.

Key words: PARP inhibitor, HD199 capsules, fluidity, dissolution, compatibility of raw materials

中图分类号:

徐克耐, 王国成, 王征, 李德馨, 李宏玲. PARP抑制剂HD199胶囊的研制[J]. 化工进展, 2020, 39(6): 2447-2452.

Kenai XU, Guocheng WANG, Zheng WANG, Dexin LI, Hongling LI. Optimization of fabrication technology of the PARP inhibitor HD199[J]. Chemical Industry and Engineering Progress, 2020, 39(6): 2447-2452.

参考文献

1	FERLAY J, SOERJOMATARAM I, DIKSHIT R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012[J]. International Journal of Cancer, 2015, 136(5): E359-E386.
2	CHEN W, ZHENG R, BAADE P D, et al. Cancer statistics in China, 2015[J]. A Cancer Journal for Clinicians, 2016, 66(2): 115-132.
3	高庆蕾, 孔北华, 尹如铁, 等. PARP抑制剂治疗复发性卵巢癌专家共识[J]. 现代妇产科进展, 2018, 27(10): 721-725.
3	GAO Q L, KONG B H, YIN R T, et al. Expert consensus on PARP inhibitors in the treatment of recurrent ovarian cancer[J]. Progress in Obstetrics and Gynecology, 2018, 27(10): 721-725.
4	MORGAN R J, ARMSTRONG D K, ALVAREZ R D, et al. Ovarian cancer, Version 1.2016, NCCN clinical practice guidelines in oncology[J]. Journal of the National Comprehensive Cancer Network, 2016, 14(9): 1134-1163.
5	张可辉, 张亮仁, 张礼和, 等. PARP-1抑制剂在抗肿瘤方面的研究进展[J]. 中国药学杂志, 2010, 45(22): 1689-1694.
5	ZHANG K H, ZHANG L R, ZHANG L H, et al. Research progress of PARP-1 inhibitors in anti-tumor[J]. Chinese Pharmaceutical Journal, 2010, 45(22): 1689-1694.
6	Center for Drug Evaluation and Research. Application number: 208447Orig1s000 chemistry review (s)[EB]. [2016-02-18]. .
7	Center for Drug Evaluation and Research. Application number: 209115Orig1s000 chemistry review (s)[EB]. [2016-02-18]. .
8	Center for Drug Evaluation and Research. Application number: 208558Orig1s000 chemistry review (s)[EB]. [2016-02-18]. .
9	Center for Drug Evaluation and Research. Application number: 211651Orig1s000 chemistry review (s)[EB]. [2017-02-14]. .
10	郑云龙, 王进美, 孙正琪, 等. 壳聚糖/明胶抗菌微胶囊的制备及其应用[J]. 化工进展, 2020, 39(3): 1137-1144.
10	ZHENG Y L, WANG J M, SUN Z Q, et al. Preparation and application of chitosan/gelatin antibacterial microcapsule[J]. Chemical Industry and Engineering Progress, 2020, 39(3): 1137-1144.
11	陈龙, 周红军, 江海科, 等. 叶面亲和型阿维菌素微胶囊的制备及pH响应性释放性能[J]. 化工进展, 2020, 39(1): 348-355.
11	CHEN L, ZHOU H J, JIANG H K, et al. Preparation and pH responsive release properties of foliar affinity avermectin microcapsules[J]. Chemical Industry and Engineering Progress, 2020, 39(1): 348-355.
12	李静涵, 魏振平. 亲水性小分子药物缓释微球制备方法的研究进展[J]. 化工进展, 2016, 35(1): 204-209.
12	LI J H, WEI Z P. Recent development on the microencapsulation of hydrophilic small molecular drugs[J]. Chemical Industry and Engineering Progress， 2016, 35(1): 204-209.
13	辛露露, 李付军, 薛飞, 等. 大蒜素/海藻酸钠/明胶/壳聚糖复合微球的制备及性能[J]. 化工进展, 2017, 36(10): 3826-3831.
13	XIN L L, LI F J, XUE F, et al. Preparation and properties of allicin/sodium alginate/gelatin/chitosan composite microspheres[J]. Chemical Industry and Engineering Progress, 2017, 36(10): 3826-3831.
14	古一雯. 微粉硅胶在制剂工艺中的应用[J]. 安徽医药, 2008, 12(10): 981-982.
14	GU Y W. Application of silica gel powder in preparation technology[J]. Anhui Medical and Pharmaceutical Journal, 2008, 12(10): 981-982.
15	SADEK H M, OLSEN J L, SMITH H L, et al. A systematic approach to glidant selection[J]. Pharmaceutical Development and Technology, 1982, 6(2): 43-62.
16	解立斌, 霍军生, 黄建. 食品粉粒体混合: 混合机理与混合均匀度影响因素探讨[J]. 中国食品添加剂, 2011(4): 32-36.
16	XIE L B, HUO J S, HUANG J. Food powder mixing: the research on mixing mechanism and factors influence mixing homogeneity[J]. China Food Additives, 2011(4): 32-36.
17	WITHEY R J, MAINVILLE C A. A critical analysis of a capsule dissolution test[J]. Journal of Pharmaceutical Sciences, 1969, 58(9): 1120-1126.

[1]	孙征楠, 李洪晶, 荆国林, 张福宁, 颜飚, 刘晓燕. EVA及其改性聚合物在原油降凝剂领域的应用[J]. 化工进展, 2023, 42(6): 2987-2998.
[2]	孔令冬, 史红星, 张彤, 刘香翠, 金青君. 化学组分对干水灭火剂流动性与保水性的影响[J]. 化工进展, 2021, 40(S2): 322-326.
[3]	孟戎茜, 邵圣娟, 王慧芳. 卡维地洛滴丸的制备工艺与表征[J]. 化工进展, 2019, 38(04): 1887-1893.
[4]	李瑞丽，阳思远，刘瑛. 异构化反应改善小桐梓油生物柴油的低温流动性[J]. 化工进展, 2012, 31(04): 813-819.
[5]	吕涯，陈淑芬. 热力学模型预测低温下柴油中正构烷烃的析出 [J]. 化工进展, 2007, 26(12): 1743-.
[6]	韩伟；黄凤洪；杨湄；刘昌盛；黄庆德. 生物柴油低温流动性及改进方法研究进展 [J]. 化工进展, 2007, 26(10): 1395-.

PARP抑制剂HD199胶囊的研制

Optimization of fabrication technology of the PARP inhibitor HD199

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 6

编辑推荐

Metrics

本文评价